Henk Streefkerk is a physician scientist (MD PhD) with clinical experience in Ear- / Nose- / Throat surgery and a PhD in Neurovascular surgery. Working experience is both in big pharma (>10 years) and bio-tech (>5 years). Henk started his pharma career as a clinical pharmacologist at Organon and Actelion. He then be-came a Translational Medicine Expert at Novartis. After moving into senior safety role, he first led the safety-related aspects of the global marketing authorization application of a heart failure drug (Entresto), followed by the same for a breast cancer drug (Kisqali). At PIQUR, as Chief Medical Officer, he led the global Clinical Development Team to manage 8 global clinical studies in various stages using a Pi3K/mTor inhibitor (bimiralisib). In view of existing quality and budget constraints, Henk has re-structured the clinical and safety departments of various biotech companies, successfully passing health authority inspections (SwissMedic / ANSM) after setting up the clinical and safety modules of the quality system. He is a co-founder of a MedTech company (Rivia.ch) which develops and commercializes software to support keeping medical oversight of clinical trials. He also setup the quality management system and information security management system according to ISO 9001 and ISO 27001/GDPR. Henk founded his own consultancy company (Streefkerk Life Sciences Consultancy), providing CMO-, Medical Director-, and Drug Safety Officer services to small biotech companies in Europe and in the USA, and is currently working as CEO of Amarna Therapeutics BV, a preclinical gene therapy company in the Netherlands.
